No connection

Search Results

PTCT vs TGTX

PTCT
PTC Therapeutics, Inc.
NEUTRAL
Price
$72.43
Market Cap
$6.0B
Sector
Healthcare
AI Confidence
80%
TGTX
TG Therapeutics, Inc.
NEUTRAL
Price
$36.96
Market Cap
$5.9B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
PTCT
8.44
TGTX
13.34
Forward P/E
PTCT
29.81
TGTX
15.01
P/B Ratio
PTCT
-28.74
TGTX
8.17
P/S Ratio
PTCT
3.46
TGTX
9.58
EV/EBITDA
PTCT
7.55
TGTX
45.15

Profitability

Gross Margin
PTCT
70.98%
TGTX
83.66%
Operating Margin
PTCT
-49.57%
TGTX
26.22%
Profit Margin
PTCT
39.44%
TGTX
72.56%
ROE
PTCT
--
TGTX
102.75%
ROA
PTCT
23.26%
TGTX
9.39%

Growth

Revenue Growth
PTCT
-22.7%
TGTX
78.0%
Earnings Growth
PTCT
--
TGTX
-6.1%

Financial Health

Debt/Equity
PTCT
--
TGTX
0.39
Current Ratio
PTCT
2.35
TGTX
4.1
Quick Ratio
PTCT
2.2
TGTX
2.91

Dividends

Dividend Yield
PTCT
--
TGTX
--
Payout Ratio
PTCT
0.0%
TGTX
0.0%

AI Verdict

PTCT NEUTRAL

PTCT presents a paradoxical profile: it boasts a perfect Piotroski F-Score of 9/9, indicating strong short-term financial improvement, yet suffers from negative revenue growth (-22.70%) and heavy insider selling. While the current P/E of 8.44 appears attractive, the jump to a Forward P/E of 29.81 suggests a significant expected decline in earnings. The stock is currently trading at a premium to its growth-based intrinsic value of $60.06, though analyst targets remain optimistic at $87.87. Overall, the strong balance sheet liquidity (Current Ratio 2.35) offsets the operational volatility, but the lack of growth and insider confidence warrants a neutral stance.

Strengths
Perfect Piotroski F-Score (9/9) indicating strong fundamental health trends
High Gross Margin (70.98%) reflecting strong pricing power or low COGS
Strong liquidity position with a Current Ratio of 2.35
Risks
Significant negative revenue growth (-22.70% YoY and Q/Q)
Heavy insider selling (16 transactions, 0 buys) including CEO and COO
Extreme earnings volatility with massive surprise swings (e.g., -1097.5% recent surprise)
TGTX NEUTRAL

TGTX exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and exceptional profitability margins, yet it faces a significant valuation gap. The stock is trading at $36.96, which is nearly double its Graham Number ($16.79) and Intrinsic Value ($19.39). While revenue growth is explosive at 78%, the company has missed earnings estimates in four consecutive quarters with an average surprise of -41.54%, and YoY earnings growth has turned negative (-6.10%). The disconnect between strong top-line growth and failing bottom-line expectations creates a high-risk profile despite the 'Buy' analyst consensus.

Strengths
Exceptional profit margins (72.56%) and gross margins (83.66%)
Strong liquidity with a Current Ratio of 4.10 and Quick Ratio of 2.91
Explosive YoY revenue growth of 78.00%
Risks
Severe valuation premium over Graham and Intrinsic value baselines
Consistent earnings misses (0/4 beats in the last 4 quarters)
Negative YoY earnings growth (-6.10%) despite revenue surge

Compare Another Pair

PTCT vs TGTX: Head-to-Head Comparison

This page compares PTC Therapeutics, Inc. (PTCT) and TG Therapeutics, Inc. (TGTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile